SG Americas Securities LLC cut its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 50.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,021 shares of the medical research company’s stock after selling 12,139 shares during the period. SG Americas Securities LLC’s holdings in PRA Health Sciences were worth $1,325,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Fagan Associates Inc. boosted its position in shares of PRA Health Sciences by 8.4% in the third quarter. Fagan Associates Inc. now owns 17,610 shares of the medical research company’s stock worth $1,940,000 after acquiring an additional 1,370 shares during the last quarter. Wellington Shields Capital Management LLC acquired a new stake in shares of PRA Health Sciences in the third quarter worth approximately $551,000. Skandinaviska Enskilda Banken AB publ boosted its position in shares of PRA Health Sciences by 46.3% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 57,800 shares of the medical research company’s stock worth $6,369,000 after acquiring an additional 18,300 shares during the last quarter. Dupont Capital Management Corp boosted its position in shares of PRA Health Sciences by 589.8% in the third quarter. Dupont Capital Management Corp now owns 24,900 shares of the medical research company’s stock worth $2,744,000 after acquiring an additional 21,290 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in shares of PRA Health Sciences in the third quarter worth approximately $5,884,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts recently issued reports on the stock. Evercore ISI initiated coverage on shares of PRA Health Sciences in a research report on Thursday, October 4th. They issued an “inline” rating and a $120.00 target price on the stock. Robert W. Baird lifted their price target on shares of PRA Health Sciences from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Tuesday, September 11th. BidaskClub cut shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday. UBS Group initiated coverage on shares of PRA Health Sciences in a research report on Tuesday, October 9th. They set a “neutral” rating on the stock. Finally, SunTrust Banks lifted their price target on shares of PRA Health Sciences to $120.00 and gave the company a “buy” rating in a research report on Monday, November 5th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. PRA Health Sciences presently has an average rating of “Buy” and a consensus price target of $111.50.
PRAH opened at $106.34 on Friday. The company has a market cap of $7.20 billion, a PE ratio of 33.23, a PEG ratio of 1.60 and a beta of 0.77. PRA Health Sciences Inc has a 52-week low of $79.20 and a 52-week high of $121.98. The company has a debt-to-equity ratio of 1.22, a quick ratio of 0.89 and a current ratio of 0.89.
PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, October 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.06. The company had revenue of $717.60 million for the quarter, compared to analyst estimates of $729.63 million. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The business’s quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 earnings per share. Equities research analysts predict that PRA Health Sciences Inc will post 3.93 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “PRA Health Sciences Inc (PRAH) Shares Sold by SG Americas Securities LLC” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/12/07/pra-health-sciences-inc-prah-shares-sold-by-sg-americas-securities-llc.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Further Reading: Growth Stocks
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.